Wells Fargo & Company Lowers Enovis (NYSE:ENOV) Price Target to $39.00

Enovis (NYSE:ENOV) had its price objective lowered by investment analysts at Wells Fargo & Company from $40.00 to $39.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 46.62% from the company’s previous close.

Other analysts have also issued reports about the stock. Evercore set a $32.00 price target on shares of Enovis in a research report on Monday, July 6th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Enovis in a research report on Friday. UBS Group reiterated a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. BTIG Research increased their target price on shares of Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Enovis Stock Up 1.1%

NYSE:ENOV traded up $0.29 during trading hours on Friday, hitting $26.60. 322,621 shares of the company’s stock traded hands, compared to its average volume of 1,094,209. The firm has a market cap of $1.53 billion, a P/E ratio of -1.33 and a beta of 1.34. Enovis has a twelve month low of $19.14 and a twelve month high of $34.28. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock’s fifty day moving average price is $24.54 and its two-hundred day moving average price is $23.95.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the prior year, the business earned $0.79 EPS. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased a total of 4,200 shares of company stock valued at $92,084 in the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ENOV. AQR Capital Management LLC lifted its stake in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the last quarter. Empowered Funds LLC increased its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. Finally, Amundi raised its holdings in Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after buying an additional 9,762 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted EPS of $0.90, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million also slightly exceeded estimates and increased 3.2% year over year. Enovis Second Quarter Earnings Results
• Positive Sentiment: Reconstructive sales were a key growth driver, rising 8% on a reported basis and 6% organically. Total second-quarter sales grew 3% reported and 5% organically, supporting the company’s long-term growth strategy. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, signaling continued analyst confidence in Enovis’ potential despite near-term execution concerns. BTIG Research Price Target Report
• Neutral Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue guidance of $2.3 billion to $2.4 billion and EPS guidance of $3.52 to $3.73. The EPS range brackets the roughly $3.54 consensus estimate, offering limited near-term guidance upside. Enovis 2026 Second Quarter Results Presentation
• Negative Sentiment: Investors reacted negatively to commentary characterizing quarterly performance as softer than expected. Although the company beat consensus estimates, the modest overall sales growth and lack of an upward guidance revision appear to have raised concerns about momentum and execution. Enovis Shares Drop After Second Quarter Earnings

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.